XERS News and Press, Xeris Pharmaceuticals Inc. From 11/09/23

2023-11-09 07:03:05 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings: On Track To Be Cash Flow Positive Xeris Biopharma's Financial Pathway: Growth Amid Challenges Xeris Pharmaceuticals Q3 2023 Earnings Preview Xeris Biopharma tightens FY23 revenue v...

Achieved record revenue of $48.3M – a 27% increase from prior quarter, and a 63% increase from same period prior year Tightens full-year 2023 revenue guidance from $155M-$165M to $160M-$165M Ended Q3 with $66.0M in cash, cash equivalents and short-term investments and remai...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

2023-11-08 12:51:26 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings: On Track To Be Cash Flow Positive Xeris Biopharma's Financial Pathway: Growth Amid Challenges Xeris Biopharma tightens FY23 revenue view to $155M-$165M from $145M-$165M Seeking Alp...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Xeris Biopharma Holdings Inc. (XERS) is expected to report $-0.12 for Q3 2023

2023-10-16 14:13:43 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings: On Track To Be Cash Flow Positive Xeris Biopharma's Financial Pathway: Growth Amid Challenges Xeris Biopharma Holdings, Inc. (XERS) Q2 2023 Earnings Call Transcript Xeris Pharmaceu...

Raises year-end cash, cash equivalents, and short-term investment guidance from $55M-$65M to $65M-$70M 2023 Cash Utilization expected to be $52M-$57M Tightens 2023 Total Revenue guidance from $145M-$165M to $155M-$165M Received $6M milestone payment for successfully formul...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that on September 26, 2023, it and Xeris Pharmaceuticals, Inc...

2023-09-14 21:41:10 ET Summary Xeris Biopharma Holdings Inc. is making strong progress on the top line and is on track to achieve a positive cash flow breakeven point in 2023. The company holds a substantial number of patents globally, contributing to its success in the pharmaceut...